From: Impact of neoadjuvant treatment on total mesorectal excision for ultra-low rectal cancers
Characteristics | Group A (n = 69) | Group B (n = 58) | Group C (n = 53) | P value |
---|---|---|---|---|
Mean(range)Age (yrs) | 70.6(33-88) | 63.1(30-88) | 61.2(37-89) | NS |
Gender | Â | Â | Â | Â |
   Male | 36 | 35 | 35 | NS |
   Female | 33 | 23 | 18 |  |
Comorbidities | Â | Â | Â | NS |
ASA status | Â | Â | Â | NS |
   1 | 11 | 9 | 13 |  |
   2 | 44 | 43 | 34 |  |
   3 | 13 | 6 | 6 |  |
   4 | 1 | 0 | 0 |  |
Type of Surgery | Â | Â | Â | Â |
   APR | 53 | 49 | 32 | 0.04 |
   ULAR | 16 | 9 | 21 |  |
Intent of Surgery | Â | Â | Â | NS |
   Curative | 62 | 54 | 49 |  |
   Palliative | 7 | 4 | 4 |  |
Approach (Lap/Open) | 16/53 | 12/46 | 10/43 | NS |
Median(range)Operating time(mins) | 174.5(80-340) | 185.3(75-420) | 181.8(100-340) | NS |
Median(range)Blood loss intraop (mls) | 601(50-3000) | 842(99-4200) | 654(99-2000) | NS |
Pathological tumor stage | Â | Â | Â | Â |
   1 | 28 | 8 | 2 |  |
   2 | 19 | 28 | 13 |  |
   3 | 16 | 16 | 34 |  |
   4 | 4 | 1 | 4 |  |
Tumor differentiation | Â | Â | Â | NS |
   Poor | 8 | 8 | 12 |  |
   Moderate | 52 | 38 | 39 |  |
   Well | 5 | 4 | 1 |  |
Neurovascular involvement | 14 | 13 | 29 | NS |